Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Address
245 FIRST STREET
CAMBRIDGE, MA 02142
Founded
2007
Number of Employees
167
Website
http://www.akebia.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
$68 | - | - | - | - | $426 | - | - | - | - | - | $247 |
| Average Price | $11.43 | - | - | - | - | $7.70 | - | - | - | - | - | $8.06 |
| # Shares Purchased | 5,910 | - | - | - | - | 55,324 | - | - | - | - | - | 30,617 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | -91.3% | - | - | - | - | -87.0% | - | - | - | - | - | -87.6% |
| S&P 500 Return to Date | 181.9% | - | - | - | - | 93.1% | - | - | - | - | - | 137.5% |
| Excess Total Return | -273.1% | - | - | - | - | -180.1% | - | - | - | - | - | -225.1% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | 3% | - | - | - | - | 2% | - | - | - | - | - | 3% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at AKBA make a trade.
Creating a free account takes less than one minute